Antiplatelet properties of a novel, non-NO-based soluble guanylate cyclase activator, BAY 41-2272.
about
NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potentialHeme-dependent and independent soluble guanylate cyclase activators and vasodilation.Inhibition of mitochondrial respiration by nitric oxide rapidly stimulates cytoprotective GLUT3-mediated glucose uptake through 5'-AMP-activated protein kinaseStimulation of soluble guanylyl cyclase inhibits mesangial cell proliferation and matrix accumulation in experimental glomerulonephritis.Riociguat (BAY 63-2521) and warfarin: a pharmacodynamic and pharmacokinetic interaction study.Soluble guanylate cyclase agonists inhibit expression and procoagulant activity of tissue factorTargeting soluble guanylate cyclase for the treatment of pulmonary hypertension.The anti-aggregating effect of BAY 41-2272, a stimulator of soluble guanylyl cyclase, requires the presence of nitric oxide.Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease.Antigrowth properties of BAY 41-2272 in vascular smooth muscle cells.Novel roles of cAMP/cGMP-dependent signaling in platelets.Regulation of sGC via hsp90, Cellular Heme, sGC Agonists, and NO: New Pathways and Clinical Perspectives.Characterization of the human alpha1 beta1 soluble guanylyl cyclase promoter: key role for NF-kappaB(p50) and CCAAT-binding factors in regulating expression of the nitric oxide receptor.Activation of haem-oxidized soluble guanylyl cyclase with BAY 60-2770 in human platelets lead to overstimulation of the cyclic GMP signaling pathway.The sGC stimulator riociguat inhibits platelet function in washed platelets but not in whole blood.Nitric Oxide-Independent Soluble Guanylate Cyclase Activation Improves Vascular Function and Cardiac Remodeling in Sickle Cell Disease.
P2860
Q24656131-9C633FC2-BF83-4D9B-90F4-FE08C9CB0892Q27692662-D8441A02-BE34-4FD4-8644-79CA3456917FQ28571968-63E6E8DA-43C6-4E9E-AA15-653AB5ABA417Q33209298-70712DBD-9D26-4A07-AC37-A7BDCD50CE88Q33447738-087BBC39-29A5-4B6F-9C91-0A7FB2E41A12Q34122462-26AF4E07-0F51-4228-ACE6-5E8143AC52C0Q34179857-9DE6CCC5-E133-44C8-A9D6-93259A6055BBQ34389020-B61EAF91-E015-4B16-99A1-DA6FAA469081Q35010064-F9E9E2DA-091F-4045-8958-1AD50E46BEF3Q37193830-C191ED39-57AE-4AF3-96EE-F8CC8E01716FQ37964007-3937E506-06B9-411A-9DE6-FB92A98290A3Q38777323-3B5B6E6E-626B-4C12-9661-80CDC59C1BF8Q40088433-1F7F519B-3D0D-4121-A7B5-F1AA1E5EAF7DQ41329824-7DDC8859-77B1-4B1E-9204-387EA867FACEQ43119916-09E9B316-03FD-4114-8B3E-4ACD649FF051Q52738823-65B07C0A-E81B-4C89-ACED-50A365559E70
P2860
Antiplatelet properties of a novel, non-NO-based soluble guanylate cyclase activator, BAY 41-2272.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Antiplatelet properties of a n ...... yclase activator, BAY 41-2272.
@en
Antiplatelet properties of a n ...... yclase activator, BAY 41-2272.
@nl
type
label
Antiplatelet properties of a n ...... yclase activator, BAY 41-2272.
@en
Antiplatelet properties of a n ...... yclase activator, BAY 41-2272.
@nl
prefLabel
Antiplatelet properties of a n ...... yclase activator, BAY 41-2272.
@en
Antiplatelet properties of a n ...... yclase activator, BAY 41-2272.
@nl
P1476
Antiplatelet properties of a n ...... cyclase activator, BAY 41-2272
@en
P2093
Salvador Moncada
P304
P356
10.1016/S1537-1891(03)00046-6
P577
2003-10-01T00:00:00Z